Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab as Bridge/Consolidation in Relapsed/Refractory B-cell Lymphomas Eligible for ASCT
NCT07387848Phase 2Recruiting
- Sponsor
- American University of Beirut Medical Center
- Start
- Aug 2026
- Primary completion
- Dec 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), B cell lymphoma, sponsored by American University of Beirut Medical Center. Started Aug 2026; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B cell lymphoma
Beyond the preview
Go deeper on NCT07387848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387848.